HELMBRECHTS, Germany—Raumedic A.G. has signed a partnership and distribution agreement with Chinese-based Woke Medical.
The deal pertains to the exclusive distribution of Raumedic's Neurovent-branded neurosurgical catheters in China. Raumedic said in a news release that China is one of the strongest growing markets in medical engineering with significant growth also coming from special products used in neurosurgery.
"With the concluded contract between Woke Medical and Raumedic, we will participate in one of the fastest growing and largest markets in the world with our Neurovent catheters," Raumedic CEO Martin Bayer said in a statement. "Last spring we opened our new U.S. headquarters in North Carolina, where we realized our concept, 'local business to local people.' On the basis of this contract, we can now also implement this concept in China."
Woke Medical CEO Tiger Zhang and Bayer signed the long-term contract to foster closer collaboration in November. The agreement marked the beginning of the approval process of Raumedic's products in China.
"Through the targeted use of Raumedic probes for pressure, temperature and oxygen partial pressure in the brain, severe complications can be averted for the patient," Ingo Bartels, manager of Raumedic's Clinics Division, said in a statement. "Important functions of the body and sensory performance remain intact."
Raumedic processes medical-grade thermoplastics polymers and silicones to develop and manufacture of tubing, molded parts, catheters and components for the medical and pharmaceutical industries. The firm operates four production sites in Germany and the U.S.